Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Is Eli Lilly Stock Overvalued?

TheMotleyFool

0 0

Pharma behemoth Eli Lilly (NYSE: LLY) posted better-than-expected fourth-quarter results ahead of the opening bell this morning. Specifically, the drugmaker topped Factset's consensus revenue estimate for the three-month period by a healthy 3.38% and Wall Street's non-GAAP earnings-per-share forecast by a striking 13.8%. Those are exceptional quarterly results by any measure.

Nonetheless, Lilly's shares don't come across as a screaming buy, despite the company's industry-leading levels of top- and bottom-line growth in the most recent quarter. Here's why investors may want to stick to the sidelines with this blue-chip pharmaceutical stock right now.

Image source: Getty Images.

Source Fool.com

Like: 0

LLY

Share